Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study

Maximilian J. Hochmair; Alessandro Morabito; Desiree Hao; Cheng Ta Yang; Ross A. Soo; James C.H. Yang; Rasim Gucalp; Balazs Halmos; Lara Wang; Angela Märten; Tanja Cufer

doi:10.2217/fon-2019-0346

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng Ta Yang, Ross A. Soo, James C.H. Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Cufer

Medicine

Research output: Contribution to journal › Review article

17 Scopus citations

Abstract

Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

Original language	English (US)
Pages (from-to)	2905-2914
Number of pages	10
Journal	Future Oncology
Volume	15
Issue number	25
DOIs	https://doi.org/10.2217/fon-2019-0346
State	Published - Jan 1 2019

Keywords

NSCLC
T790M
afatinib
osimertinib
sequential

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2019-0346

Fingerprint Dive into the research topics of 'Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study'. Together they form a unique fingerprint.

Cite this

Hochmair, M. J., Morabito, A., Hao, D., Yang, C. T., Soo, R. A., Yang, J. C. H., Gucalp, R., Halmos, B., Wang, L., Märten, A., & Cufer, T. (2019). Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study. Future Oncology, 15(25), 2905-2914. https://doi.org/10.2217/fon-2019-0346

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : Updated analysis of the observational GioTag study. / Hochmair, Maximilian J.; Morabito, Alessandro; Hao, Desiree; Yang, Cheng Ta; Soo, Ross A.; Yang, James C.H.; Gucalp, Rasim ; Halmos, Balazs; Wang, Lara; Märten, Angela; Cufer, Tanja.

In: Future Oncology, Vol. 15, No. 25, 01.01.2019, p. 2905-2914.

Research output: Contribution to journal › Review article

Hochmair, Maximilian J. ; Morabito, Alessandro ; Hao, Desiree ; Yang, Cheng Ta ; Soo, Ross A. ; Yang, James C.H. ; Gucalp, Rasim ; Halmos, Balazs ; Wang, Lara ; Märten, Angela ; Cufer, Tanja. / Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : Updated analysis of the observational GioTag study. In: Future Oncology. 2019 ; Vol. 15, No. 25. pp. 2905-2914.

@article{365ebed5c7174b918cbc095811edb8b0,

title = "Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study",

abstract = "Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.",

keywords = "NSCLC, T790M, afatinib, osimertinib, sequential",

author = "Hochmair, {Maximilian J.} and Alessandro Morabito and Desiree Hao and Yang, {Cheng Ta} and Soo, {Ross A.} and Yang, {James C.H.} and Rasim Gucalp and Balazs Halmos and Lara Wang and Angela M{\"a}rten and Tanja Cufer",

year = "2019",

month = jan,

day = "1",

doi = "10.2217/fon-2019-0346",

language = "English (US)",

volume = "15",

pages = "2905--2914",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "25",

}

TY - JOUR

T1 - Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer

T2 - Updated analysis of the observational GioTag study

AU - Hochmair, Maximilian J.

AU - Morabito, Alessandro

AU - Hao, Desiree

AU - Yang, Cheng Ta

AU - Soo, Ross A.

AU - Yang, James C.H.

AU - Gucalp, Rasim

AU - Halmos, Balazs

AU - Wang, Lara

AU - Märten, Angela

AU - Cufer, Tanja

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

AB - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

KW - NSCLC

KW - T790M

KW - afatinib

KW - osimertinib

KW - sequential

UR - http://www.scopus.com/inward/record.url?scp=85071633846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071633846&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0346

DO - 10.2217/fon-2019-0346

M3 - Review article

C2 - 31370698

AN - SCOPUS:85071633846

VL - 15

SP - 2905

EP - 2914

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 25

ER -